

Curriculum vitae

Alexis Edwin Te, M.D.

Date of Preparation: April 28, 2010

A. BACKGROUND INFORMATION

Office Address: Brady Prostate Center
Department of Urology
Weill Cornell Medical College of Cornell University
New York Presbyterian Medical Center
525 East 68th Street, Suite F9 West, Box 261
New York, New York 10021
(212) 746-4811 Office
(212) 746-5329 Office Fax

B. EDUCATIONAL BACKGROUND

High School: Polytechnic Preparatory Country Day School
1976-1980 Brooklyn, NY
Awarded: 1980 High School Diploma
Cum Laude Honor Society

College: Yale University
1980-1984 New Haven, CT
Awarded: 1984 BS- Molecular Molecular Biophysics & Biochemistry
Associate Member of Sigma Xi Research Society

Medical School Cornell University Medical College
1984-1988 New York, NY
Awarded: 1988 Medical Doctorate

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

Postgraduate Training

Intern: Department of Surgery
1988-1989 Columbia Presbyterian Medical Center
New York, NY

Resident: Department of Surgery
1989-1990 Columbia Presbyterian Medical Center
New York, NY

Resident:
1990-1994
Department of Urology
J. Bentley Squire Urologic Clinic
Columbia Presbyterian Medical Center
New York, NY

Chief Resident:
1994
Department of Urology
J. Bentley Squire Urologic Clinic
Columbia Presbyterian Medical Center
New York, NY

Fellowship:
1995
Neurourology and Urodynamics
Department of Urology
College of Physician and Surgeons, Columbia University
New York, NY

Academic Positions:

1994-1995
Fellow in Neurourology and Urodynamics
College of Physicians & Surgeons, Columbia University

1995-2000
Assistant Professor of Urology
Department of Urology
College of Physicians and Surgeons, Columbia University

2000-2001
Assistant Clinical Professor of Urology
Department of Urology
College of Physicians and Surgeons, Columbia University

2001-2009
Adjunct Assistant Professor of Urology
Department of Urology
College of Physicians and Surgeons, Columbia University

2000-2002
Assistant Professor of Urology
Department of Urology
Weill Medical College of Cornell University

2002-2009
Associate Professor of Urology
Department of Urology
Weill Medical College of Cornell University

2002-2010
Professor of Urology
Department of Urology
Weill Medical College of Cornell University

Hospital Positions:

1994-1995	Clinical Assistant in Urology J. Bentley Squier Urologic Clinic Columbia Presbyterian Medical Center
1994-2000	Attending in Surgery Department of Urology Helen Hayes Hospital West Haverstraw, NY
1995-2000 1995-1996	Junior Assistant Attending in Urology Director of Neurourology & Urodynamics Department of Urology St. Luke's-Roosevelt Hospital Center
1995-2009 1995-2000	Assistant Attending in Urology Co-Director of Incontinence Care Center J. Bentley Squier Urologic Clinic Columbia Presbyterian Medical Center
1996-2004 1996-2006 2006-2010	Director of the Incontinence Care Center Assistant in Surgery Courtesy Staff Neurourology and Urodynamics Laboratory Division of Urology Maimonides Medical Center
2002-Present	Consultant-NYPH Hospital for Special Surgery
2000-Present	Director of the Brady Prostate Center and Urodynamics Attending in Urology Department of Urology New York Presbyterian Medical Center/ Weill Cornell Center

Other employment: N/A

D. Licensure, Board Certification and Malpractice:

1. Licensure

a. State	Date of Issue	Date of last renewal
New York State	1989	2008

c. DEA Certification Current

2. Board Certification

Full Name of Board: American Board of Urology

Certificate # 11868

Date of 1st Issue: February 28, 1998

Date of Issue: February 28, 2008

Date of Next Recertification: February 28, 2018

3. Malpractice Insurance

Do you have Malpractice Insurance? Yes

Name of Provider: MCIC

Premiums paid by WCMC

E. Memberships in Associations:

Title	Organization	Date Joined
Member	American Urological Association	1994
Member	American Urologic Association/New York Section	1994
Member	American Medical Association	1994
Member	Philippino Chinese Medical Association	1995
Member	Medical Society of the State of New York	1994
Member	Chinese American Medical Association	2002
Member	Endourologic Society	1998
Member	Society of Urodynamics and Female Urology	1998
Member	American Academy of Science	2000
Member	Society of International Urology/ Societe Urologie International	2006
Member	National Association For Continence	2005
Fellow	The New York Academy of Medicine	2008

F. Honors and Awards:

Sigma Xi Research Society, Associate Member, 1984

Outstanding Achievements in Medicine, Philippine Chinese Medical Association, 1995

Outstanding Young Man, Philippine Chinese Association of America, 1996

New York Harvest Award, UST Medical Alumni Association, 1997

Rising Star Award, Poly Preparatory Country Day School Board of Alumni, 1999

Medicine Achievement Award, Philippine Chinese Association, 2002

Distinguished Physician Award, Philippine Chinese Medical Association 2004

SUFU Best Video Award- 1st Prize 2008

AUA Best Video Award-1st Prize 2008
SuperDocs 2008, 2009, 2010
Castle Connolly: Best Doctor in NY Metro Area: Urology 2007, 2008, 2009, 2010
Consumer's Research Council of America: Top Physicians 2004-2009
Best Doctors in America Database: 2009, 2010
Marquis Who's Who in America 2009

Cornell Patents

1. Patent Application Submitted April 9, 2009 to US Patent Office. Assigned to Cornell University. **Te AE**, Rey D, Batts C. NANOPARTICLE-MEDIATED MICROWAVE THERMOTHERAPY AND TISSUE TREATMENT METHODS BASED THEREON

G. HOSPITAL/INSTITUTIONAL AFFILIATION

1. Primary Hospital Affiliation: New York Presbyterian Hospital (Cornell)
2. Other Hospital Affiliation: Hospital for Special Surgery

H. EMPLOYMENT STATUS

1. Name of Current Employer(s): Weill Cornell Medical College
2. Employment Status: Full-time salaried by Cornell

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT

1. Teaching (e.g., specific teaching functions, courses taught, dates)
Resident Education (Grands Rounds, Mortality and Morbidity): 1990- Present
Fellowship Education (Co-Mentor and Fellowship Supervisor): 1995-Present
Cornell Fellows Trained:

Jaspreet Sandhu, MD	2004-2005
William Jaffe, MD	2004-2005
Balaji Reddy, MD	2004-2006
Ricardo Gonzalez, MD	2005-2006
-NY Academy of Medicine Valentine Fellow	
Rajiv Saini, MD	2006-2007
Eddie Zoltan, MD	2007-2008
Doreen Chung, MD	2008-Present
Richard Lee, MD	2009- Present

BioMedical Graduate Education (Summer Mentor):2005-Present
Weill-Ithaca Cornell Biomedical Summer Immersion Program
Clerkship Sponsor
Cameron Bardliving 2008

2. Clinical care

Focus on voiding dysfunction in adults and diseases of the prostate and bladder including neurourology and urodynamics, female urology, incontinence, benign prostatic hyperplasia, prostatitis, prostate cancer, chronic pelvic pain syndromes, and lower urinary tract pathology: 1995-Present

3. Administrative duties

Institutional Responsibilities:

Founding Webmaster of http://urology.columbia.edu Department of Urology, Columbia University Website	1995-2000
Public Relations Committee Department of Urology, Columbia University	1995-2000
Computer Committee Department of Urology, Columbia University	1995-2000
Director of Neurourology & Urodynamics Department of Urology, St. Luke's-Roosevelt Hospital Center	1995-1996
Co-Director of Incontinence Care Center J. Bentley Squier Urologic Clinic, Columbia Presbyterian Medical Center	1995-2000
Director of the Incontinence Care Center Division of Urology, Maimonides Medical Center	1996-2004
Compliance Leader Department of Urology, Cornell University	2002
Formulary and Therapeutics Committee New York Presbyterian Medical Center	2003-Present
Institutional Review Board Member Weill Medical College of Cornell University	2008-Present
Director of the Brady Prostate Center and Urodynamics Department of Urology, New York Presbyterian, Weill Cornell Medical College	2000-Present

4. Research

Current Research Experience:

Cornell University, Department of Urology 1995- Present
Weill Cornell Medical College New York,NY
Associate Professor of Urology
Areas of Current Research: Benign Prostatic Hyperplasia (BPH), Therapies in BPH,
Incontinence, Prostatitis, Neurourology and Urodynamics, Female Urology, Interstitial
Cystitic, Laser Surgery, Prostate Cancer

Past Research Experience

Columbia University 1994-1995
College of Physicians and Surgeons New York,NY
Department of Urology
Sponsors: Steven A. Kaplan, M.D. & Carl A. Olsson, M.D.
Topic: Transurethral Electrovaporation of the Prostate

Columbia University 1992-1994
College of Physicians and Surgeons New York,NY
Department of Urology
Sponsors: Steven A. Kaplan,M.D., Ridwan Shabsigh,M.D.,Ralph Buttyan,Ph.D.& Carl
Olsson, M.D.
Topic: Neurotrophic factors in developing and diabetic bladders and penis
Castration-Induced Apoptosis in the Rat Penis

Cornell University Medical College July 1987
Brady Urology Research Laboratory New York,NY
Sponsor: E. Darracott Vaughan,Jr.,M.D.
Topic: Intraperitoneal infusion of alkaline irrigating solutions used in uric acid stone
treatment

University of California, San Francisco Summer 1985
Department of Biophysics & Biochemistry San Francisco,CA
Sponsor: Robert Fletterick, Ph.D.
Topic: Isolation of human liver glycogen phosphorylase gene from human genomic
cDNA library

Yale University Academic Year 1983-1984
Department of Molecular Biophysics & Biochemistry New Haven, CT
Sponsor: W. Dean Rupp, Ph.D.
Topic: The DNA sequence of the uvrB gene in E. Coli.

University of California, San Francisco Summer 1983
Department of Biophysics & Biochemistry San Francisco, CA
Sponsor: Robert Fletterick, Ph.D.
Topic: The DNA sequence of human muscle glycogen phosphorylase

Yale University Medical School
 Department of Cardiovascularpathophysiology
 Sponsor: S. Evans Downing, M.D.
 Topic: Biochemical assay to measure heart muscle scars in rabbits

Academic year 1982-83
 New Haven, CT

The New York Blood Center
 Department of Cell Biochemistry
 Sponsor: Jack Goldstein, Ph.D.
 Topic: Protein purification of N- Acetyl-D-Galactosaminodase

Summer 1982
 New York, NY

The Jackson Laboratory
 Sponsor: David E. Harrison, Ph.D.
 Topic: Water solubility changes of collagen in aging mice skin

Summer 1979
 Bar Harbor, Maine

<u>Current Percent Effort (%)</u>	<u>Does the activity involve WMC students/researchers? (Yes/No)</u>
Teaching 10%	Yes
Clinical Care 50%	No
Administration 5%	No
Research 35%	Yes

J. RESEARCH SUPPORT

Principle Investigator

1. Clinical efficacy and tolerability/safety of tolterodine prolonged release capsules. A open labeled multinational extended study in patients with symptoms of overactive bladder
 Funding Source: Pharmacia UpJohn
 Duration: 2000-2001
2. A randomized, double-blind, placebo controlled, fixed dose study to evaluate the safety and efficacy of LU 25-109 in the treatment of adult patients with overactive bladder.
 Funding Source: Forest Laboratories
 Duration: 1999-2000
2. The long-term efficacy and safety of alfuzosin 10mg OD (once a day) on the risk of acute urinary retention and the need for surgery in patients with BPH (benign prostatic hyperplasia). A two-year, randomized, multicenter, double-blind, parallel group, placebo-controlled study.
 Funding Source: Sanofi-Synthelabo
 Duration: 2001-2005
3. A double-blind randomized parallel group study of alfuzosin 10mg OD (once a day) versus placebo in the management of acute urinary retention in patients with a first episode due to BPH (Benign Prostatic Hyperplasia)
 Funding Source: Sanofi-Synthelabo
 Duration: 2001-2003

4. A Multi Center Study of the Tolerability, Efficacy, and Safety of Transperineal Prostatic Block or Transrectal Ultrasound Block as Primary Methods of Local Anesthesia for Interstitial Laser Thermal Therapy In An Outpatient Clinic Setting In Subjects with Symptomatic Benign Prostatic Hyperplasia
Funding Source: Ethicon Endosurgery
Duration: 2001-2002
5. A Double-Blind Placebo-Controlled, Pilot Study to Teat Patients with Moderate to Severe Progressive Benign Prostatic Hypertrophy with Phenoxybenzamine (Dibenzyline).
Funding Source: Wellspring Pharmaceuticals Inc.
Duration: 2001-2003
6. A Postmarket data collection study of the uroflometry effects and symptom alleviations of the Thermoflex™ System in patients suffering form benign prostatic hyperplasia (BPH)
Funding Source: Argomed, Inc.
Duration: 2000-2002
7. Prostate Specific Antigen (PSA) Density of the Transition Zone in Ethnically Diverse Men DAMD17-99-1-9041 P.I. % effort: 25
Funding Source: Department of Defense
Duration: 1999
8. The Use of a Bipolar Electrovaporization Technique utilizing the Gyrus PlasmaKinetic Electrosurgical System with Isotonic Saline Irrigating Solution in the Treatment of Benign Prostatic Hyperplasia
Funding Source: Gyrus
Duration: 2000-2001
9. Clinical efficacy and tolerability/safety of tolterodine prolonged release capsules and tolterodine immediate release tablets vs placebo. A randomized, double-blind, placebo-controlled, multinational study in patients with symptoms of overactive bladder
Funding Source: Pharmacia UpJohn
Duration: 1999-2000
10. A Multi-Center Clinical Evaluation of the 80W KTP Laser Prostatectomy for the Treatment of Benign Prostatic Hyperplasia
Funding Source: Laserscope, Inc.
Duration:2002-2003
11. Evaluation of RDP58 in a mouse model of acute and chronic interstitial cystitis
Funding Source: Sangstat, Inc.
Duration: 2002-2003
12. A Phase I/II Dose Escalation Study to Asses the Safety, Tolerability, and Preliminary Efficacy of Transurethral Photodynamic Therapy with QLT0074 for Benign Prostatic Hyperplasia
Funding Source: QLT, Inc
Duration: 2003-2004
14. A Randomized, Double- Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy- Detectable Prostate Cancer

- Funding Source: Glaxo Smith Kline
Duration: 2003-2005
- 15 Protocol H6D-MC-LVHK: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 weeks in Men with Signs and Symptoms of BPH
Funding Source: Lilly Icos
Duration:2006-2008
 - 16 A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Urodynamic and Safety of YM178 in Male Subjects with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)-I-3
Funding Source: Astellas
Duration: 2006-2007
 - 17 A Pilot Study to Measure the Efficacy of Long-Acting Tolterodine on Continued Detrusor Overactivity in Patients that Have Undergone Treatment for Bladder Outlet Obstruction
Funding Source: Pfizer
Duration: 2007-Present
 18. Randomized Double-Blind Placebo Controlled Trial of Intradetrusor Injections of Botox for the Treatment of Urinary Incontinence Secondary to Benign Prostatic Hyperplasia BTX0621
Funding Source: Allergan
Duration: 2007-Present
 19. Examination of High Power (120W) Laser Energy in Canine Prostatectomy
Funding Source: AMS
Duration: 2006
 20. A Prospective Evaluation of the Greenlight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia
Funding Source: Laserscope
Duration: 2006-2007
 21. Sanofi-Synthelabo Prospective, Observational Registry and Patient Survey of the Management of Men with Benign Prostatic Hyperplasia (BPH): BPH Registry and Patient Survey
Funding Source: Sanofi-Aventis
Duration: 2005-2007
 22. A Randomized, Double-Blind, Placebo-Controlled, Dose Comparison Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Funding Source: Threshold
Duration: 2005-2006

Co- Investigator

1. Microwave Thermotherapy vs. TURP, a randomized comparative study
PI: Steven A. Kaplan

- | | | |
|----|--|---|
| 2. | Funding Source: Urologix, Inc., Minneapolis, MN.
Peripheral Sacral Nerve Stimulation for the treatment of Voiding Dysfunctions
PI: Steven A. Kaplan | Duration: 1996-1999 |
| 3. | Funding Source: Medtronic, Inc., Minneapolis, MN.
Medical Therapy of BPH Study (MTOPS): A 6 year study
UO1 DK46418 – 04
PI: Steven A. Kaplan | Duration: 1997-2000
Co-PI % effort: 20 |
| 4. | Funding Source: NIH
Electrovaporization of the prostate in men with benign prostatic hyperplasia
PI: Steven A. Kaplan | Duration: 1995-2000 |
| 5. | Funding Source: Circon ACMI
Vaporization versus TURP in the management of BPH
PI: Steven A. Kaplan | Duration: 1994-1996 |
| 6. | Funding Source: Circon ACMI
Urodynamic and Multiethnic Variability of Men Treated by Minimally Invasive Surgical Therapies DK4641
PI: Steven A. Kaplan | Duration: 1995-1996
Co-PI % effort: 10 |
| 7. | Funding source: NIH
Complementary and Alternative Medical Therapy to Urology Symptoms
DK
PI: Steven A. Kaplan | Duration: 2002-2009
Co-PI% effort: 10 |
| | Funding Source:NIH | Duration: 2004-2011 |

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Editorial Responsibilities:

Assistant Editor, Journal of Urology	2007-Present
Web Alerts Editor, Current Urology Reports	2000-Present
Literature Alerts Editor, Current Urology Reports	2000-2004
Section Editor, Current Urology Reports (Prostatitis and Infections)	2000-Present
Section Editor, Current Prostate Reports (Prostatitis and Infection)	2000-Present
Section Editor, Journal of EndoUrology (Survey)	2007-Present
Urology Journal (reviewer)	
Journal of Endourology (reviewer)	
Journal of Urology (reviewer)	
British Journal of Urology (reviewer)	
Neurourology and Urodynamics (reviewer)	

National Committee Responsibilities:

American Urological Association:	
Chair, Audio Visual Committee	2008-2010
Vice Chair, Audio Visual Committee	2007

Voting Audio Visual Committee Member 2006- Present
Abstract Committee Reviewer
Abstract Committee Team Leader
Annual Meeting Faculty Member
AUA BPH Course Director
Member of the AUA Education Council 2008- Present

National Institute of Health

Task Force Member, Interstitial Cystitis Epidemiology Task Force Meeting
NIDDK/NIH, Bethesda, MD 10/29/03
Grant Reviewer, NIDDK CP Collaborative Network Grant Review Meeting,
3/17/03
Grant Reviewer, NIDDK IC Collaborative Network Grant Review Meeting,
3/18/03
Grant Reviewer, NCI Novel Technologies for InVivo Imaging Grant Review
Meeting 3/23/04
Consultant, NIDDK Prostate Basic and Clinical Research Strategic Planning
Meeting 7/10/07
Grant Reviewer, NIH, O'Brien Center for Urology 07/27-28/2009

Philippino Chinese American Medical Association 2008-Present
Board of Governors, Member

National Association for Continence 2008-Present
Board Member

NY Academy of Medicine 2007-Present
Executive committee member of the Urology section.

L. BIBLIOGRAPHY

Peer Review Publications:

1. **Te AE**, Colombel M, Koo HP, Kaplan SA, Buttyan R, Olsson CA, Shabsigh R. Castration-Induced Apoptosis in the Rat Penis. Surgical Forum 1992; 48: 724-725.
2. **Te AE**, Koo HP, Kaplan SA, Buttyan R, Olsson CA, Shabsigh R. Neurotrophic Factors in the Diabetic Rat Penis. Surgical Forum 1993; 49: 758-760.
3. Kaplan SA, **Te AE** & Jacobs BZ. Urodynamic evidence of vesical neck obstruction in men with " chronic non-bacterial " prostatitis and the therapeutic role of the endoscopic incision of the bladder neck. J Urol. 1995; 152:2063-2065.
4. **Te AE**, Santarosa R, Buttyan R, Greene L, Koo HP, Kaplan SA, Olsson CA & Shabsigh R. Neurotrophic Factors in the Rat Penis. J Urol.1994; 152:2167-2172.

5. Kaplan SA, **Te AE**, Blaivas JG: Urodynamic findings in patients with diabetic cystopathy. *J Urol*. 1995; 153:342-344.
6. Kaplan SA, **Te AE**. Transurethral Electro vaporization of the Prostate (TVP): A novel method of treating men with benign prostatic hyperplasia. *Urology* 1995; 45: 566-573.
7. Kaplan SA, **Te AE**. A comparative study of transurethral resection of the prostate using a modified electro vaporizaing loop and transurethral laser vaporization of the prostate. *J. Urol*. 1995; 154: 1785-90.
8. Kaplan SA, **Te AE**, Pressler LB, Olsson CA. Transition zone index (TZI): A novel method of assessing benign prostatic hyperplasia: correlation with symptoms, uroflow and detrusor pressure. *J Urol*. 1995; 154: 1764-69.
9. Bowers DL, Te A, Hibshoosh H, Sawczuk IS. Renal hemangiopericytoma. Case report and review of the literature. *Urol Int*. 1995;55(3):162-6.
10. Kaplan SA, Bowers DA, **Te AE**, Olsson CA: Differential diagnosis of prostatism: 12-year retrospective analysis of symptoms, urodynamics and satisfaction with therapy. *J Urol*. 1996; 155: 1305-1308.
11. Kaplan SA, Olsson CA & **Te AE**: The American Urological Association symptom score in the evaluation of men with lower urinary tract symptom: At 2 years of followup, does it work?. *J Urol*. 155:1971-1974, 1996.
12. Kaplan SA, Ikeguchi EF, Santarosa RP, Meade D' Alisera P, Hendriks J, **Te AE** & Miller MI: Etiology of voiding dysfunction in men less than 50 years of age. *Urology*. 47: 836-839, 1996.
13. Kaplan SA, Santarosa RP & **Te AE**: Comparison of fascial and vaginal wall slings in the management of intrinsic sphincter deficiency. *Urology*. 47: 885-889, 1996.
14. McKiernan JM, Kaplan SA, Santarosa RP, **Te AE**, Sawczuk IS: Transurethral vaporization of bladder cancer. *Urology* 48(2): 207-10
15. **Te AE**, Santarosa R, Kaplan SA.:Electro vaporization of the prostate: electosurgical modification of standard resection in 93 patients with benign hyperplasia. *J Endourol* 11(1):71-5, 1997.
16. Kaplan SA, Santarosa RP, **Te AE**: Transurethral electro vaporization of the prostate: one year experience. *Urology* 48(6):876-81, 1996.
17. Kaplan SA, Santarosa RP, D' Alisera PM, Fay BJ, Ikeguchi EF, Hendricks J, **Te, AE**: Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option. *J Urol* 157(6):2234-7, 1997
18. Kaplan SA, Reis RB, Cologna A, Suaid HJ, Martins ACP, Kohn IJ, **Te AE**: Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. *Urology* 52(1):12-16, 1998.
19. Kaplan SA, **Te AE**, Ikeguchi E, Santarosa RP: Safety and efficacy of alpha blockers in the treatment of men over the age of 80 with benign prostatic hyperplasia. *Br J Urol* 1997 Dec;80(6):875-9
20. Kaplan SA, Reis RB, Staiman VB, **Te AE**: Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic Counterparts?. *Br J Urol* 1998, 82: 804-807
21. Kaplan SA, Reis RB, Kohn IJ, Ikeguchi EF, Laor E, **Te AE**, Martins ACP: Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. *Urology* 1999, 53:481-486.

22. Kaplan SA, Reis RB, Kohn IJ, Shabsigh R, **Te AE**: Combination therapy using oral alpha blockers and intracavernosal injection in men with erectile dysfunction. *Urology* 1998, 52(5): 739-43.
23. Kaplan SA, Laor E, Fatal M, **Te AE**: Transurethral resection of the prostate versus transurethral electrovaporization of the prostate: a blinded, prospective comparative study with 1 years followup. *J Urology* 1998, 159(2):454-8.
24. Reis RB, **Te AE**, Cologna AJ, Suaid HJ, Kaplan SA: Interstitial Thermometry in Men Undergoing Electrovaporization of the Prostate. *J Endourology* 1999, 13 (1): 53-56.
25. Kaplan SA, Stifelman M, Avillo C, Reis RB and **Te AE**: Detrusor contraction duration (DCD) may predict response to alpha blocker therapy for lower urinary tract symptoms. *Eur Urol* 2000 Mar;37(3):314-7.
26. Kaplan SA, **Te AE**, Young GPH, Andrade A, Cabelin MA, Ikeguchi EF: Prospective analysis of 373 consecutive women with stress urinary incontinence treated with a vaginal wall sling: the Columbia- Cornell university experience, *J Urol.* 2000 Nov;164(5):1623-7.
27. Choi J, Ikeguchi EF, Lee SW, Choi HY, **Te AE**, Kaplan SA: Is the Higher Prevalence of Benign Prostatic Hyperplasia Related to Lower Urinary Tract Symptoms in Korean Men due to a High Transition Zone Index? *Eur Urol.* 2002 Jul;42(1):7-11.
28. **Te AE**: A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions. *Clin Ther.* 2002 Jun;24(6):851-61; discussion 837.
29. Kaplan SA, Ghafar MA, Volpe MA, Lam JS, Fromer D, **Te AE**. PSA response to finasteride challenge in men with a serum PSA greater than 4ng/ml and previous negative prostate biopsy: preliminary study. *Urology.* 2002 Sep;60(3):464-8.
30. **Te AE**: Editorial Comment: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. *Urol.* 62(2): 264.
31. **Te AE**. The development of laser prostatectomy. *BJU Int.* 2004 Feb;93(3):262-5.
32. Kaplan SA, Volpe MA, **Te AE**. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. *J Urol.* 2004 Jan;171(1):284-8.
33. **Te AE**. Editorial Comment: Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. *Urology.* 2004 Nov;64(5):1003-1004.
34. **Te AE**, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA, Malek RS. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. *J Urol.* 2004 Oct;172(4 Pt 1):1404-8.
35. Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, **Te AE**. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. *Urology.* 2004 Dec;64(6):1155-9.
36. Sandhu JS, Ng CK, Gonzalez RR, Kaplan SA, **Te AE**. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. *J Endourol.* 2005 Dec;19(10):1196-8.
37. Kaplan SA, Walmsley K, **Te AE**. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. *J Urol.* 2005 Dec;174(6):2273-5.

38. González RR, Fong T, Belmar N, Saban M, Felsen D, **Te AE**. Modulating bladder neuroinflammation: RDP58, a novel anti-inflammatory peptide, reduces inflammation and nerve growth factor production in experimental cystitis. *J Urol* 2005 Feb; 173(2): 630-4.
39. Lee R, Gonzalez RR, **Te AE**. The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia. *World J Urol*. 2006 Sep;24(4):405-9.
40. Staskin DR, **Te AE**. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. *BJU Int*. 2006 Jun;97(6):1256-61.
41. **Te AE**, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. *BJU Int*. 2006 Jun;97(6):1229-33.
42. Monoski MA, Gonzalez RR, Sandhu JS, Reddy B, **Te AE**. Urodynamic predictors of outcomes with photoselective laser vaporization prostatectomy in patients with benign prostatic hyperplasia and preoperative retention. *Urology*. 2006 Aug;68(2):312-7.
43. El-Hakim A, Leung RA, Richstone L, Kim TS, **Te AE**, Tewari AK. Athermal Robotic Technique of prostatectomy in patients with large prostate glands (>75 g): technique and initial results. *BJU Int*. 2006 Jul;98(1):47-9.
44. Kaplan SA, Gonzalez RR, **Te AE**. Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction. *Eur Urol*. . *Eur Urol*. 2007 Jun;51(6):1717-23.
45. **Te AE**. Current state of the art photoselective vaporization prostatectomy: laser therapy for benign prostatic hyperplasia. *Prostate Cancer Prostatic Dis*. 2007 Mar;10 Suppl 1:S2-5.
46. Lemack GE, Amundsen C, Badlani G, Griebing T, Peters K, Rodriguez L, Singla A, Smith C, Sullivan M, Te A. Highlights from the combined Society of Urodynamics and Female Urology, and International Society of Pelvic Neuromodulation annual meeting. *J Urol*. 2007 Feb;177(2):691-5.
47. **Te AE**. Editorial Comment on the Manuscript, "Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: A prospective randomized multicenter study", *Urol*.2007 Jan; 69(1): 96-97
48. **Te AE**. Is transurethral microwave thermotherapy comparable to transurethral resection for BPH? *Nat Clin Pract Urol*. 2007 Sep;4(9):478-9. Epub 2007 Jul 31.
49. Tewari AK, Bigelow K, Rao S, Takenaka A, El-Tabi N, Te A, Vaughan ED. Anatomic restoration technique of continence mechanism and preservation of puboprostatic collar: a novel modification to achieve early urinary continence in men undergoing robotic prostatectomy. *Urology*. 2007 Apr;69(4):726-31.
50. **Te AE**. Current state of the art photoselective vaporization prostatectomy: laser therapy for benign prostatic hyperplasia. *Prostate Cancer Prostatic Dis*. 2007 Mar;10 Suppl 1:S2-5.
51. Lee R, Saini R, Zoltan E, **Te AE**. Photoselective vaporization of the prostate using a laser high performance system in the canine model. *J Urol*. 2008 Oct;180(4):1551-3. Epub 2008 Aug 16.
52. **Te AE**. Should vardenafil be used for the treatment of lower urinary tract symptoms associated with BPH?. *Nat Clin Pract Urol*. 2008 Oct;5(10):536-7. Epub 2008 Aug 19.

53. Saini R, Gonzalez RR, **Te AE**. Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link. *Curr Urol Rep*. 2008 Jul;9(4):314-9.
54. O'Leary MP, Wei JT, Roehrborn CG, Miner M, BPH Registry and Patient Survey Steering Committee (**Te AE**). Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. *BJU Int*. 2008 Jun;101(12):1531-5. Epub 2008 Apr 28.
55. Kaplan SA, Walmsley K, **Te AE**. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. *J Urol*. 2008 May;179(5 Suppl):S82-5.
56. Schwartz MJ, Hwang DH, Hung AJ, Han J, McClain JW, Shemtov MM, **Te AE**, Sosa RE, Vaughan ED Jr, Scherr DS. Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy. *Cancer*. 2008 Apr 15;112(8):1718-25.
57. Tewari A, Jhaveri J, Rao S, Yadav R, Bartsch G, Te A, Ioffe E, Pineda M, Mudaliar S, Nguyen L, Libertino J, Vaughan D. Total reconstruction of the vesico-urethral junction. *BJU Int*. 2008 Apr;101(7):871-7.
58. Lee R, **Te AE**, Kaplan SA, Sandhu JS. Temporal trends in adoption of and indications for the artificial urinary sphincter. *J Urol*. 2009 Jun;181(6):2622-7. Epub 2009 Apr 16.
59. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA; BPH Registry and Patient Survey Steering Committee (**Te AE**). Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. *Urology*. 2009 Mar;73(3):562-6. Epub 2009 Jan 23.
60. Tan GY, El Douaihy Y, **Te AE**, Tewari AK. Scientific and technical advances in continence recovery following radical prostatectomy. *Expert Rev Med Devices*. 2009 Jul;6(4):431-453

Invited Review Publications:

1. Kaplan SA, **Te AE**: Uroflowmetry & Urodynamics. *Urologic Clinics of North America* 1995; 22: 309-20.
2. **Te AE** , Kaplan SA: Transurethral Electrovaporization of the Prostate (TVP): A electrosurgical advancement of the standard TURP. *Current Surgical Techniques in Urology* 1995; 8:1-9.
3. **Te AE** , Reis R, Kaplan SA: Transurethral Electrovaporization of the Prostate (TVP): A novel modification of the standard TURP. *Contemporary Urology* 1995; 7:74-83.
4. **Te AE**, Kaplan SA: Electrovaporization of the Prostate. *Current Opinion in Urology* 1996; 6: 2-9.
5. Santarosa RP, **Te AE**, Kaplan SA: Minimally Invasive Procedures for Benign Prostatic Hyperplasia. *Mediguide to Urology* 1996; 9:1-6
6. **Te AE**, Kaplan SA: Transurethral electrovaporization of the Prostate. *Mayo Clin Proc* 1998 Jul;73(7):691-5
7. **Te AE** and Kaplan SA: Transurethral electrovaporization of the prostate: the year in review. *Current Opinion in Urology* 1997; 7:25-36.

8. Santarosa RP, **Te AE** and Kaplan SA: Minimally invasive procedures for benign prostatic hyperplasia: electrovaporization, lasers, heat therapy and stents. In: Mediguide for Urology. Ed: Carson CC. 1996; 9:1-6.
9. Choi J, Ikeguchi EF, **Te AE**, Kaplan SA: Review of laser prostatectomy. Urology Review, July, 1999.
10. Cabelin MC, **Te AE**, Kaplan SA: Benign prostatic hyperplasia: challenges for the new millennium. *Curr Opin Urol*. 2000 Jul;10(4):301-6.
11. Cabelin MC, **Te AE**, Kaplan SA: Transurethral vaporization of the prostate: Current Techniques. *Current Urology Reports* July 2000 1(2):116-123.
12. Kohn I, **Te AE**, Kaplan SA: Neuromodulations. *AUA Updates*; 2003.
13. Gonzalez R, **Te AE**: How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy. *Current Urology Reports*. August 2003. 4(4): 297-306.
14. Gonzalez RR, **Te AE**. Overactive bladder and men: indications for anticholinergics. *Curr Urol Rep*. 2003 Dec;4(6):429-35.
15. Sandhu J, **Te AE**. The Role of 5 AR Inhibition as Monotherapy in View of the MTOPS Data. *Current Prostate Reports*. Volume 2, Issue 1; 2004.
16. Gonzalez RR, **Te AE**. Chronic prostatitis and sensory urgency: whose pain is it? *Curr Urol Rep*. 2004 Dec;5(6):437-41.
17. Yang J, **Te AE**. Saw Palmetto and Finasteride in the Treatment of Category-III Prostatitis/Chronic Pelvic Pain Syndrome. *Curr Urol Rep*. 2005 Jul;6(4):290-5.
18. Jaffe WI, **Te AE**. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. *Curr Urol Rep*. 2005 Nov;6(6):410-8.
19. Reddy BN, González RR, **Te AE**. The implications of cytokines in chronic prostatitis and chronic pelvic pain syndrome. *Curr Prostate Rep* Nov 2005; 3(4): 189-94.
20. Gonzalez RR, **Te AE**. Is there a role for urodynamics in chronic nonbacterial prostatitis? *Curr Urol Rep*. 2006 Jul;7(4):335-8.
21. Ng CK, Gonzalez RR, **Te AE**. Refractory overactive bladder in men: update on novel therapies. *Curr Urol Rep*. 2006 Nov;7(6):456-61.
22. **Te AE**. The Next Generation in Laser Treatments and the Role of the GreenLight High-Performance System Laser. *Rev Urol*. 2006;8 Suppl 3:S24-30.
23. Lebed, BD, Jafee WI, **Te AE**. Sexual Complications of Minimally Invasive Surgical Therapy for Benign Prostatic Hyperplasia. *Current Sexual Health Reports* 2006, 3:76-82
24. **Te, AE**, Laser Prostatectomy Advance for the Prostate, *Renal & Urology News*, May 2006, pg 27
25. Lee R, Saini R, Kaplan SA, **Te AE**. A Review of Transurethral Microwave Thermotherapy. *AUA Update Series*. Volume 26 Lesson 28 Page 277-284
26. **Te AE**. The PVP procedure for BPH: Long-term outcomes. *Urology Times*. January 1, 2007 Issue.

Review Publications:

1. **Te, AE**: Literature Alerts, *Current Urology Reports* Volume 1, Issue 1; 2000
2. **Te, AE**: Literature Alerts, *Current Urology Reports* Volume 1, Issue 2; 2000
3. **Te, AE**: Literature Alerts, *Current Urology Reports* Volume 1, Issue 3; 2000

50. Sandhu J, **Te AE**: Web Alerts, Current Urology Reports, Volume 6, Issue 4; 2005
51. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 6, Issue 5; 2005
52. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 6, Issue 6; 2005
53. Sandhu J, **Te AE**: Web Alerts, Current Prostate Reports, Volume 3, Issue 1; 2005
54. Sandhu J, **Te AE**: Web Alerts, Current Prostate Reports, Volume 3, Issue 2; 2005
55. Sandhu J, **Te AE**: Web Alerts, Current Prostate Reports, Volume 3, Issue 3; 2005
56. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 3, Issue 4; 2005
57. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 7, Issue 1; 2006
48. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 7, Issue 2; 2006
49. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 7, Issue 3; 2006
50. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 7, Issue 4; 2006
51. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 7, Issue 5; 2006
52. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 7, Issue 6; 2006
53. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 4, Issue 1; 2006
54. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 4, Issue 2; 2006
55. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 4, Issue 3; 2006
56. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 4, Issue 4; 2006
57. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 8, Issue 1; 2007
58. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 8, Issue 2; 2007
59. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 8, Issue 3; 2007
60. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 8, Issue 4; 2007
61. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 8, Issue 5; 2007
62. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 8, Issue 6; 2007
63. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 5, Issue 1; 2007
64. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 5, Issue 2; 2007
65. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 5, Issue 3; 2007
66. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 5, Issue 4; 2007
67. Winfield HN, Tally GG, Wong MYC, **Te AE**, Assimios DG, Conlin M, Duchene DA, Cadeddu JA, Hemal A. Journal of Endourology. June 2007, 21(6): 563-573
68. Winfield HN, Tally GG, Wong MYC, **Te AE**, Assimios DG, Conlin M, Duchene DA, Cadeddu JA, Hemal A. Survey of Endourology 2007 J Endourology 21(11): 1235-1248
69. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 9, Issue 1; 2008
70. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 9, Issue 2; 2008
71. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 9, Issue 3; 2008
71. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 9, Issue 4; 2008
73. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 9, Issue 5; 2008
74. Ng C, **Te AE**: Web Alerts, Current Urology Reports, Volume 9, Issue 6; 2008
75. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 6, Issue 1; 2008
76. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 6, Issue 2; 2008
77. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 6, Issue 3; 2008
78. Ng C, **Te AE**: Web Alerts, Current Prostate Reports, Volume 6, Issue 4; 2008
79. Winfield HN, Tally GG, Wong MYC, **Te AE**, Assimios DG, Conlin M, Duchene DA, Cadeddu JA, Hemal A. Survey of Endourology 2008 J Endourology 22 (11): 2415-2428
80. Winfield HN, Tally GG, Wong MYC, **Te AE**, Assimios DG, Conlin M, Duchene DA, Cadeddu JA, Hemal A. Survey of Endourology 2008 J Endourology August 2008, 22(8): 1597-1608

81. G.G. Tailly, H.N. Winfield, M.Y.C. Wong, **A.E. Te**, D.G. Assimos, M.J. Conlin, D.A. Duchenne, J.A. Cadeddu, A.K. Hemal. Survey of Endourology 2008 J Endourology 22(5): 847-858.
82. G.G. Tailly, H.N. Winfield, M.Y.C. Wong, **A.E. Te**, D.G. Assimos, M.J. Conlin, D.A. Duchenne, J.A. Cadeddu, A.K. Hemal. Survey of Endourology. J Endourology. February 2009: 23(2): 209-222.
83. G.G. Tailly, H.N. Winfield, M.Y.C. Wong, **A.E. Te**, D.G. Assimos, M.J. Conlin, D.A. Duchenne, J.A. Cadeddu, A.K. Hemal. Survey of Endourology. J Endourology. June 2009, 23(6): 879-890

Book Chapters:

1. Kaplan SA, **Te AE**: Bladder Dysfunction in Diabetes, In: Paulson, ed. Problems in Urology; Neurourology and its Role in Urologic Diseases: Part I. Philadelphia: J. B. Lippincott Co., 6: 659-668. 1992.
2. **Te AE**, Kaplan SA: Pharmaceutical Treatment of BPH and its effect on indications for prostate surgery. In: Surgical Technology International III: Endourology. San Francisco: Universal Medical Press, Inc.1994.
3. **Te AE**, Kaplan SA: Urodynamics and BPH. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, eds. Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media, LTD., 187-198. 1996.
4. **Te AE**, Kaplan SA: Prostatic Endoprosthetics. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, eds. Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media, LTD. 453-462.1996.
5. **Te AE**, Kaplan SA: Electrovaporization of the Prostate: Advance Application of Electrosurgical Principles to the Treatment of Benign Prostatic Hyperplasia. In: Kirby RS, O'Leary MP, ed. Recent Advances in Urology 7. London: Churchill Livingstone, 1998.
6. Santarosa RP, **Te AE**, Kaplan SA: Transurethral resection, incision and ablation of the prostate. In: Graham SD, ed. Glenn's Urologic Surgery, 5th edition. Philadelphia: Lippincott, Williams and Wilkins. 921-931.1998.
7. **Te AE**, Santarosa RP, Kaplan SA: Tranurethral Electrovaporization of the Prostate. In: Resnick MI, Thompson IM, ed. Surgery of the Prostate. London: Churchill Livingstone.295-307. 1998.
8. **Te AE**, Kaplan SA: Electrovaporization Principles. In: Narayan P, ed. Benign Prostatic Hyperplasia. London: Churchill Livingstone, 325-334. 2000.
9. Kohn IJ, **Te AE** and Kaplan SA: Urodynamics of prostatitis. In: Nickel JC ed., Textbook of prostatitis. Oxford: Isis Medical Media, LTD. 2000.
10. Ikeguchi EF, **Te AE**, Choi J, Kaplan SA: Bladder Outlet Obstruction in Males. In: Appel RA,ed. Current Clinical Urology: Diagnosis and Treatment. Totowa, NJ: Humana Press Inc. 2000.
11. **Te AE**, Ikeguchi EF, Kaplan SA: Transurethral Electrovaporization of the Prostate. In: Recent Advances in Endourology. Vol. 2/ Treatment of BPH. Tokyo: Springer-Verlag. 157-166, 2000.

12. **Te AE**, Kaplan SA: Complication of Minimally Invasive Surgery for BPH. In: Taneja SS, Smith RB, Ehrlich RM, ed. *Complication of Urologic Surgery*, 3rd edition. Philadelphia: W. B. Saunders, 244-256, 2001.
13. Cabelin M, **Te AE** and Kaplan SA: Urogenital physiology. In: Gonzalez, Myers, Edelman, Leiberman and Downey, ed., *Physiological Basis of Rehabilitation Medicine*. 191-208, 2001.
14. **Te AE**, Kaplan SA: Electrovaporization of the Prostate. In: Miller PD, Eardley I, Kaplan SA, ed. *Benign Prostatic Hyperplasia: Laser and Heat Therapy*. London: Martin Dunitz. 2001.
15. Volpe M, Ghafar MA, **Te AE**: Diagnosis and Management of Obstruction after Anti-Incontinence Surgery. In: Carlin BI and Leong FC, ed. *Female Pelvic Health and Reconstructive Surgery*. New York, NY: Marcel Dekker, Inc. 2002.
16. Sandhu JS, **Te AE**: Open Prostatectomy. In: Kaplan SA and Cabelin M, ed. *Atlas of Urologic Clinics of North America*. Philadelphia, PA: W. B. Saunders. April 2002.
17. Cabelin MA, Ghafer MA, **Te AE**, Kaplan SA: Transurethral Vaporization of the Prostate. In: Kaplan SA and Cabelin M, ed. *Atlas of Urologic Clinics of North America*. Philadelphia, PA: W. B. Saunders. 45-49, 2002.
18. Sandhu J, **Te AE**. Benign Prostatic Hyperplasia (BPH). In: Martini L, ed. *Encyclopedia of Endocrine Diseases: 4 Volumes*. San Diego, Ca. Academic Press 2004
19. **Te AE**, Ikeguchi EF, Choi J, Kaplan SA: Urodynamics and benign prostatic hyperplasia. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P., ed. *Textbook of benign prostatic hyperplasia*. 2nd Edition. Oxford: Isis Medical Media Ltd. 2005, pg 241-253.
20. Hyman MJ, **Te AE**: Stents, TUIP and Electrovaporization. In: Kaplan SA, Atala A and Partin A, ed. *Minimally Invasive Alternatives in Urology*. New York, NY: Marcel Dekker, Inc. 2005.
21. Gonzalez RR, Lee R, Sandhu JS, **Te AE**. Laser Prostatectomy In *Atlas of the Prostate*, Eds. Scardino PT, Slawin K. 3rd Edition, 2006.
22. 21. Gonzalez RR, Tyagi T, **Te AE**. Neurologic Disorders. In: Cardozo L and Staskin D, Ed. *Textbook of Female Urology and Gynecology*. United Kingdom. 2006. pg 565-582.
23. Schiff JD, **Te AE**. Electrosurgery of the Prostate: Improvements in TURP-Treatment and Outcomes. In: Smith AD et al, Ed. *Smiths' Textbook of Endourology*. 2nd Edition 2007. pg.645-651
24. Lee R, Sandhu J, Gonzalez RR, **Te AE**. Laser Prostatectomy. In: Smith AD et al, Ed. *Smiths' Textbook of Endourology*. 2nd Edition 2007. pg. 617- 626.
25. 25. **Te AE**. Benign Prostatic Hyperplasia. In: Morey A. Shokes DA, Ed. *The American Urological Association Educational Review Manual in Urology*. 1st Edition 2007.
26. Ulchaker JC, **Te AE**. Benign Prostatic Hyperplasia. In: Morey A. Shokes DA, Ed. *The American Urological Association Educational Review Manual in Urology*. 2nd Edition 2009.

Multimedia Publications:

1. **Te AE**, Kaplan SA: Transurethral electrovaporization of the prostate. Endourology on CD-ROM. Vol. 1, Editors; Paoletti P & Benelli R, IPE Multimedia, Firenze, Italy.1997.
2. **Te AE**, Ghafar MA, Merriweather T, Volpe MA, Ikeguchi E, Kaplan SA. Nomogram and urodynamic predictors of urinary retention in men with BPH and Bladder Outlet Obstruction. Poster #1096. Annual AUA Meeting 2001 CD ROM of Top 120 Poster Presentation.
3. Kaplan SA, Blute M, Bruskewitz RC, **Te AE**, Larson TR, Utz W, Ugarte R, Mayer R: Long term efficacy and durability in 345 patients treated with transurethral microwave thermotherapy for benign prostatic hyperplasia: five year results. Poster #1153 .Annual AUA Meeting 2002 CD ROM of Top 120 Poster Presentation.
4. González RR, **Te AE**. Photoselective vaporization of the prostate with the 80 watt quasicontinuous KTP laser for the treatment of benign prostatic hyperplasia. DVD Video. American College of Surgeons, Cine Clinics, Clinical Congress, October 12, 2004, New Orleans, LA CC I: Urological surgery CD Collection Cat Number VS1090.
5. Sandhu JS, **Te AE**, Eilber KS. The Male Bulbourethral Sling. Society for Female Urology and Urodynamics. SUFU Annual Meeting, Grand Bahamas. Best Video Award. 2005
6. Sandhu JS, **Te AE**. Photoselective Vaporization of the Prostate - The Vaporization Incision Technique for Large Volume Prostates. AUA Annual Meeting. 2005 *J Urol* 2005, 173(4): 366.
7. **Te AE**, Gonzalez R, Sandhu JS Photoselective Vaporization of the Prostate - The Vaporization Incision Technique (PVP-VIT) in DVD titled, Il Laser Per Il Trattamento Dell' Iperplasia Prostatica Benigna, Editor, Roberto Benelli, Italy, 2005.
8. **Te AE** Laser Prostatectomy for the Treatment of BPH Q & A from Prostatic Hyperplasia (BPH) 2006: Are We Treating a New Disease? In Topics in Urology Audio Series. Moderator: P Rogers. Oakstone Medical Publishing. CME Accredited Series. Fall 2006.
9. **Te AE**. Urodynamics and BPH slide set. Timely Topics in Medicine. Prious Sceince. www.ttmed.com.12/12/07
10. **Te AE**. Urodynamcis and BPH article. Timely Topics in Medicine. Prious Sceince. www.ttmed.com.12/12/07

Abstracts:

1. **Te AE**, Buttyan R, Koo HP, Greene LA, Kaplan SA, Olsson CA & Shabsigh R: Abundant expression of nerve growth factor (NGF) in the rat penis, a developmental study. *J Urol.* 147:239A, 1992.
2. **Te AE**, Buttyan R, Koo HP, Shabsigh R, Olsson CA & Kaplan SA: Nerve growth factor in diabetic cystopathy. *J Urol.* 147:350A, 1992.
3. Koo HP, Buttyan R, **Te AE**, Kaplan SA, Olsson CA & Shabsigh R: Neurotrophin expression in diabetic rat penis: a new insight into pathogenesis of erectile dysfunction. *J Urol.* 147:240A, 1992.
4. Shabsigh R, Buttyan R, Koo HP, Kaplan SA, Olsson CA & **Te AE**: Expression of neurotrophins: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) in the rat penis. *J Urol.* 147:318A, 1992.

5. Brown W, **Te AE**, Olsson CA & Benson MC: Management of complications of continent urinary diversions. *J Urol.* 147:390A, 1992.
6. **Te AE**, Buttyan R, Koo HP, Olsson CA & Kaplan SA: Nerve growth factors in diabetic cystopathy. *Neurourology and Urodynamics.* 11(4):303, 1992.
7. **Te AE**, Buttyan R, Koo HP, Shabsigh R, Olsson CA & Kaplan SA: Nerve growth factors in diabetic cytopathy. *Diabetes.* 41(Sup 1):140A, 1992.
8. Kaplan SA, **Te AE** & Blaivas JG: Urodynamic findings in patients with diabetes and voiding symptoms: surprising results. *International Continence Society. 22nd Ann. Mtg. Abstract 115*, 1992.
9. **Te AE**, Buttyan R, Koo HP, Kaplan SA, Olsson CA & Shabsigh R: Neurotrophic Factors in the diabetic rat penis: an extended study. *J Urol.* 149:247A, 1993.
10. Santarosa RP, **Te AE**, Koo HP, Buttyan R, Kaplan SA, Olsson CA & Shabsigh R: Androgen Deprivation and Apoptosis in Rat Erectile Tissue. *J Urol.* 151:494A, 1994.
11. **Te AE**, Olsson CA & Kaplan SA: Use of the AUA-BPH treatment guidelines in men with symptomatic benign prostatic hyperplasia (BPH): At one year, is it effective?. *J Urol.* 151:507A, 1994.
12. Shabsigh R, **Te AE**, Koo HP, Kaplan SA, Olsson CA & Shabsigh: Localization of nerve growth factor beta (NGF) in the rat penis by in-situ hybridization. *Society for Basic Urologic Research Fall Symposium, Rochester, MN*, 1991.
13. **Te AE**, Colombel M, Koo HP, Kaplan SA, Buttyan R, Olsson CA & Shabigh R: Castration- induced apoptosis in the rat penis. *ACS Annual Mtg. Chicago II*, 1992.
14. Shabsigh R, **Te AE** & Fisch H: Cavernous electromyography as an indication of adequate smooth muscle relaxation during duplex ultrasonography. *5th World Meeting on Impotence. Milan, Italy*, 1992.
15. **Te AE**, Buttyan R, Koo HP, Greene L, Kaplan SA, Olsson CA & Shabsigh R: Neurotrophins in the rat penis. *5th World Meeting on Impotence. Milan, Italy*, 1992.
16. Santarosa RP, **Te AE**, Koo HP, Raymond J, Columbel M, Olsson CA, Buttyan R & Shabsigh R: Testosterone sensitivity of the erectile tissue of the rat penis to castration. *7th World Meeting on Impotence. Singapore, ISIR*, 1994.
17. **Te AE**, Kaplan SA, Dann JA. Transurethral electrovaporization of the prostate (TVP): A novel method for treating men with benign prostatic hyperplasia. *J Urol.* 1995; 153: 436A.
18. **Te AE**, Santarosa R, Kaplan SA. Transurethral electrovaporization of prostate (TVP): A modification on the standard TURP. *J Endourology* 1995; 9: S58.
19. Kaplan SA, Santarosa RP, **Te AE**: Electroevaporization of the prostate for symptomatic benign prostatic hyperplasia: the 1 year experience. *J Urol.* 1996, 155(5):405A.
20. Reis RB, Cologna AJ, Suaid HJ, Kaplan SA, **Te AE**: Electroevaporization of the prostate (VAP): a comparison of roller electrode configurations for resecting prostate tissue. *J Urol.* 1996, 155(5):406A.
21. Laor E, Kaplan SA, **Te AE**, Tolia BM and Reid RE: Laser vaporization of "large" prostate glands: long term follow - up. *J Urol.* 1996, 155(5):706A.
22. Reis RB, Cologna AJ, Suaid HJ, **Te AE** and Kaplan SA: Interstitial thermometry in men undergoing electrovaporization: is it safe? *J Urol.* 1996, 155(5):707A.
23. Kaplan SA, Santarosa RP, **Te AE**: The incidence of hypertension in men with benign prostatic hyperplasia. *XIIth European Urology Association, Paris*, 1996.

24. Kaplan SA, Laor E, Te AE: Transurethral resection of the prostate (TURP) versus electrovaporization of the prostate (VAP): a prospective, blinded comparative study of the treatment of benign prostatic hyperplasia (BPH). XXIIth European Urology Association, Paris, 1996.
25. Avillo C, Stifelman M, Te AE, Sandler P and Kaplan SA: The urodynamic parameter: detrusor contraction duration (DCD) predicts response to alpha blocker therapy for lower urinary tract symptoms (LUTS). *J Urol.*1997, 157(4): 136.
26. Te AE, Laor EL, Kaplan SA, Babayan R, Noble M, Mbust W, Bruskewitz R, Whitfield HN: Transurethral resection of the prostate (TURP) versus vaporization of the prostate utilizing a vaporizing loop (TVLOOP): a multicenter, blinded, prospective comparative study. *J Urol.*1997, 157(4): 313.
27. Te AE, Laor E, and Kaplan SA: Transurethral resection of the prostate (TURP) versus transurethral electrovaporization of the prostate (TVP): a blinded, prospective comparative study with 1 year follow - up. *J Urol.*1997, 157(4): 313.
28. Pressler LB, Santarosa RP, Te AE and Kaplan SA: The incidence of hypertension (HTN) in a population of men with benign prostatic hyperplasia (BPH): analysis based on the AUA symptom score and race. *J Urol.*1997, 157(4): 371.
29. D'Alisera PM, Stifelman M, Kohn I, Te AE, Weiner DM, Kaplan SA: Correlation of lower urinary tract symptom (LUTS) severity by International Prostate Symptom Score (IPSS) and erectile dysfunction (ED) in men over 50 years of age. *J Urol.* 1998, 159(5): 103.
30. Reis RB, Suaid HJ, Cologna AJ, Te AE, Kaplan SA: Men with lower urinary tract symptoms (LUTS) and inguinal hernias (HERN) have significantly greater bladder outlet obstruction (BOO) than men with LUTS alone. *J Urol.* 1998, 159(5): 139.
31. Reis RB, Suaid HJ, Cologna A, Martins ACP, Te AE, Kaplan SA: Intermittent therapy with alpha blocker, alfuzosin. *J Urol.* 1998, 159(5): 331.
32. Nejat RJ, Ikeguchi EF, Te AE, Reis RB, Kaplan SA: Electrovaporization of the prostate utilizing the roller ball and/or vaporizing loop for the symptomatic benign prostatic hyperplasia (BPH): The 4- year Columbia experience. *J Urol* 1999, 161(4): 391.
33. Ries RB, Martins ACP, Cologna A, Junior ST, Te AE, Kaplan SA: Long term durability of intermittent alpha blockade in the treatment of lower urinary tract symptoms (LUTS). *J Urol* 2000, 163(4): 1362.
34. Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE, Kaplan SA: Characterization of lower urinary tract symptoms and prostate parameters in Asian men compared to Caucasians, Hispanics and African - Americans. *J Urol* 2000, 163(4): 1110, 250.
35. Cabelin MA, Te AE, Ikeguchi EF, Andrade AJ, Young GPH, Kaplan SA: Prospective analysis of 327 women with stress urinary incontinence treated with vaginal wall sling: a multicenter experience. *Neurourology & Urodynamics* 2000, 19(3):323-364.
36. Cabelin MA, Hyun G, Te AE, Meade D'Alisera P, Shabsigh R, Kaplan SA. Increased incidence of depressive symptoms in women with stress urinary incontinence. *Neurourology & Urodynamics* 2000, 19(3):323-364.
37. Volpe MA, Te AE, Kaplan SA. A prospective trial using saw palmetto versus finasteride in the treatment of chronic nonbacterial prostatitis. *J Urol* 2001, 165(5): 27.
39. Te AE, Ghafar MA, Merriweather T, Volpe MA, Ikeguchi E, Kaplan SA. Nomogram and urodynamic predictors of urinary retention in men with BPH and Bladder Outlet Obstruction. *J Urol* 2001, 165(5): 267.

40. Cooper K, Littlejohn JO, **Te AE**, Kaplan SA: Disappointing long term results of transvaginal bone anchors in the treatment of stress urinary incontinence (SUI): The 3-year New York Presbyterian hospital experience. *J Urol* 2002 , 167(4): 78.
41. Rodgers JM, **Te AE**, Ghafar M, Kaplan SA, Zaontz MR, Packer M, Dean GE: Glibenclamide enhances stretch-activated contraction in rat bladders and shows protective effects in human diabetic cystopathy. *J Urol* 2002, 167 (4): 42.
42. Kaplan SA, **Te AE**: Electrovaporization of the prostate utilizing the roller ball and/or vaporizing loop for symptomatic benign prostatic hyperplasia (BPH): the 7 year Columbia experience in 650 consecutive men. *J Urol* 2002, 167 (4): 296.
43. Kaplan SA, **Te AE**: Pressure/ flow evaluation of ethnically diverse men treated by minimally invasive surgical therapies for BPH: The New York Presbyterian Hospital Experience. *J Urol* 2002, 167 (4): 366.
44. Gonzalez RR, Sher K, Fong T, **Te AE**: RDP58 reduces bladder inflammation in a murine model of acute inflammatory cystitis. *J Urol* 2003, 169 (4): 68.
45. Gonzalez RR, Sher K, Fong T, **Te AE**: The effect of DMSO on bladder inflammation in a murine model of acute inflammatory cystitis. *J Urol* 2003, 169 (4): 69.
46. Sandhu SS, Vanderbrink BA, Egan C, Kaplan SA, **Te AE**: High-power KTP photoselective laser vaporization prostatectomy for the treatment of benign prostatic hyperplasia in men with large prostates. *J Urol* 2003, 169(4): 393.
47. **Te AE**, Malloy TR, Stein BS, Ulcahker JC, Hai MA, Nseyo UO, Malek RS: Photoselective laser vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia: The first multicenter prospective trial. *J Urol* 2003, 169(4): 465.
48. Cooper K, **Te AE**, Kaplan SA: Long term safety and efficacy in 147 patients treated with prostate stents for benign prostatic hyperplasia: 12 year results. *J Urol* 2003, 169(4):465.
49. Sandhu SS, Vanderbrink BA, Egan C, Kaplan SA, **Te AE**: High-power KTP photoselective laser vaporization prostatectomy for the treatment of benign prostatic hyperplasia in men with large prostates. World Congress of Endourology, Toronto, 9/2003
50. Kaplan, SA, Walmsley K, **Te AE**. Use of muscurinic receptor antagonist as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers. *J. Urol.* 2004 171(4):243
51. **Te AE**, Kaplan SA: Dutasteride provides improvement in urodynamic parameters over 2 years: Analysis of data from the phase III dutasteride studies. *J Urol.* 2004 171(4): 359
52. Malloy TR, Stein BS, Ulcahker JC, Nseyo UO, Hai MA, Malek RS, **Te AE**: Photoselective laser vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia: 24-month results from a prospective multicenter clinical trial. *J Urol.* 2004 171(4): 399.
53. Sandhu JS, Ng CK, Gonzalez R, Kaplan SA, Te AE: High-power KTP photoselective laser vaporization prostatectomy for the treatment of benign prostatic hyperplasia in men with large prostate: The New York Presbyterian series of 64 patients. *J Urol.* 2004 171(4): 400.
54. Te AE, Sandhu JS, Gonzalez R, Egan C, Kaplan SA, Te AE: High-power KTP photoselective laser vaporization prostatectomy (PVP) versus transurethral electrovaporization of the prostate (TVP) for the treatment of benign prostatic hyperplasia (BPH): A prospective comparative trial. *J Urol.* 2004 171(4): 402.

55. Okeke Z, Walmsley K, **Te AE**, Kaplan SA: Sexual function in ethnically diverse men with Category III Prostatitis/ Chronic Pelvic Pain Syndrome. *J Urol* 2004 171(4): 60.
56. Monoski MA, Sandhu JS, González RR, **Te AE**. Urodynamic predictors of success with photoselective laser vaporization prostatectomy in patients with benign prostatic hyperplasia and preoperative retention. *J Urol* 2005, 173(4): 354.
57. **Te AE**, Sandhu JS, Reddy B, Ng CK, González RR, Kaplan SK. The first 200 patients treated with high power KTP photoselective laser vaporization prostatectomy: the New York Presbyterian experience. *J Urol* 2005, 173(4): 423.
58. Sandhu JS, **Te AE**. Electrosurgical transurethral resection of the prostate: Evaluating the training gap. *J Urol* 2005, 173(4): 34.
59. Sandhu JS, **Te AE**. Photoselective vaporization of the prostate-The vaporization incision technique for large volume prostates. *J Urol* 2005, 173(4): 366.
60. **Te AE**, Malloy TR, Stein BS, Ulcahker JC, Nseyo UO, Hai MA. Impact of prostate specific antigen and prostate volume as predictors of efficacy outcomes in photoselective vaporization prostatectomy (PVP): Analysis and results of ongoing prospective multicenter study at three years. *J Urol* 2005, 173(4): 421.
61. Malloy TR, Sandhu JS, Smith AL, Reddy B, Harryhill JF, Kaplan SA, **Te AE**. Photoselective vaporization of the prostate (PVP) in anticoagulated patients: A multicenter retrospective evaluation of feasibility. *J Urol* 2005, 173(4): 423.
62. Stein BS, **Te AE**, Malloy TR, Ulcahker JC, Nseyo UO, Hai MA. Factors influencing efficacy outcomes in photoselective vaporization prostatectomy (PVP): Analysis and results of ongoing prospective multicenter study at three years. *Urol* 2005, 66(Supplement 3A):17-18
63. Reddy B, Gonzalez RR, Sandgu JS, Kaplan SA, **Te AE**. High power KTP photoselective vaporization prostatectomy: The New York Presbyterian Experience. . *Urol* 2005, 66(Supplement 3A): 19.
64. Kaplan SA, González RR, Ogiste J, **Te AE**. Combination of an alpha-blocker, alfuzosin SR and a PDE-5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms (LUTS) and sexual dysfunction. *J Urol* 2006, 175(4): 528.
65. Kaplan SA, Kaplan JD, González RR, **Te AE**. The use of a voiding diary to evaluate urinary frequency and nocturia is a better indicator than the IPSS in assessing alpha-blocker efficacy in men with lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). *J Urol* 2006, 175(4): 438.
66. González RR, Reddy B, Chen J, Staskin DR, **Te AE**. Effects of short-term estrogen deprivation on experimental bladder inflammation. *J Urol* 2006, 175(4): 61-2.
67. Penson D, Litwin MS, Payne R, **Te AE**, Metzger C, Wei JT Do Socioeconomic Characteristics Play a Role in Treatment Choice for BPH? *J Urol* 2006, 175(4): 2.
68. Monoski MA, Gonzalez RR, Sandhu JS, Reddy B, **Te AE**. Urodynamic predictors of outcomes with photoselective laser vaporization prostatectomy in patients with benign prostatic hyperplasia and preoperative retention. 2006 SUFU Annual Meeting . Grand Bahamas 2006 February
69. Ricardo R. Gonzalez, Balaji N. Reddy, Jaspreet S. Sandhu, Steven A. Kaplan, and Alexis E. Te, High-power KTP photoselective laser vaporization prostatectomy: The New York Presbyterian Experience. 2006 SUFU Annual Meeting. Grand Bahamas 2006 February.

70. Balaji N. Reddy, R. R. Gonzalez, S. A. Kaplan, and A.E. Te, High-Power KTP Photoselective Vaporization Prostatectomy (PVP): The Cornell Experience. American Society of Laser Medicine and Surgery Annual Meeting 2006, Boston, Massachusetts ASLMS. April 6, 2006
71. **Te AE**, Gonzalez RR, Reddy B, and Kaplan SA. Photoselective laser vaporization prostatectomy-vaporization incision technique for large prostates. Western Section American Urological Association, Maui, HI October 22, 2006
72. **Te AE**, Yang JH, Gonzalez RR, Reddy B, Xi Z, Madhu M, and Kaplan SA. Safety and efficacy of photoselective laser vaporization of the prostate for benign prostatic hyperplasia (BPH) in men over 80 years. Western Section American Urological Association, Maui, HI October 22, 2006
73. Roehrborn CG, Penson D, **Te AE**, Wei JT, Nuckolls J. Why Men on Watchful Waiting for LUTS/BPH Start Medical Therapy: Findings from the USA BPH Registry & Patient Survey, Annual SIU Meeting, 2006, South Africa 11/13/06
74. Hung AJ, Schwartz MJ, Hwang DH, McClain JW, Han J, Shmetov MM, **Te AE**, Sosa RE, Vaughan ED, Scherr DS. Changes in practice patterns and outcomes of transrectal ultrasound-guided biopsy. 2007 J Urol. 177(4): 203 Suppl.
75. Roehrborn CG, Wei JT, Steers WD, Miner M, Seftel AD, **Te AE**, BPH Registry Steering Committee. Health-related quality of life is the main predictor of progression to benign prostatic hyperplasia related surgery: outcomes data from the BPH registry & patients survey. 2007 J Urol. 177(4): 495 Suppl.
76. Kaplan SA, Fisch H, Berriman SJ, Saini R, Lee R, **Te AE**, Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms, sexual dysfunction, and components of the metabolic syndrome.. 2007 J Urol. 177(4): 497 Suppl
77. Rao S, Martinez-Salamanca JI, Ramanathan R, Mandhani A, Leung R, **Te AE**, Berryhill R, Horninger W, Takennaka A, Vaughan ED, Tewari A. Total reconstruction technique of the continence mechanism following robotic prostatectomy. 2007 J Endourology 21 (Suppl 1): P28.
78. Rao S, Ramanathan R, Martinez-Salamanca JI, , Mandhani A, **Te AE**, Bartsch G, Tewari A. Total continence outcomes in patients undergoing robotic prostatectomy- A comparison of three techniques. 2007 J Endourology 21 (Suppl 1): P28.
79. Rao S, Takennaka A, Martinez-Salamanca JI, Li P, Leung R, Mandhani A, Ramanathan R, Bartsch G, **Te AE**, Tewari A. Total reconstruction technique of the continence mechanism following robotic prostatectomy. 2007 J Endourology 21 (Suppl 1): A229.
80. Saini R, **Te AE**, Tewari AK, Rao AR, Kaplan SA. Predictive factors for post prostatectomy (RP) urinary incontinence (UI) in men with pre-operative lower urinary tract symptoms (LUTS): a pilot study. Neurourology & Urodynamics 2007 26(7): 1105 Suppl
81. Lee R, Saini R, **Te AE**. Photoselective vaporization of the prostate (PVP) using the Greenlight high performance system (HPS) in the canine model. Neurourology & Urodynamics 2007 26(7): 1094 Suppl.
82. Monoski M, **Te AE**, Kaplan SA. Lower urinary tract symptoms associated with obstructive sleep apnea improve after treatment with continuous positive airway pressure. Neurourology & Urodynamics 2007 26(7): 1063 Suppl.

83. Zoltan E, Lee RR, Saini R, Egan CA, Kaplan SA, **Te AE**. Comparative evaluation of the high power 532 nm laser systems, 120 Watt (HPS) VS 80 Watt (KTP), for photoselective vaporization of the prostate (PVP) of large glands with vaporization incision technique (VIT) J Urol. 2008 179 (4): 626 Suppl.
84. Gonzalez RR, Soni SD, Reddy B, Madhu M, Kaplan SA, **Te AE**. Octogenarians with symptomatic benign prostatic hyperplasia (BPH) have similar outcomes after photoselective vaporization of the prostate (PVP) compared to a younger cohort despite increased comorbidities J Urol. 2008 179 (4): 631 Suppl.
85. Kaplan SA, Zoltan E, **Te AE**. Safety and efficacy of tolterodine, solifenacin, and darifenacin in men with overactive urinary tract symptoms (LUT) on alpha-blockers with persistent overactive bladder symptoms (OAB) J Urol. 2008 179 (4): 701 Suppl.
86. Rao S, Tu J, Jhaveri J, Yadav R, Leung R, Martinez-Salamanca JI, Takenaka A, **Te AE**, Bartsch G, Vaughan ED, Tewari A. Distribution of peri-prostatic nerves in the fascial planes around the prostate- Implications for the technique of nerve sparing radical prostatectomy. J Urol. 2008 179 (4): 228 Suppl.
87. Jhaveri J, Chhabra P, **Te AE**, Takenaka A, Tu J, Yadav R, Rao S, Leung R, Salamanca J, Bartsch G, Menon A, Vaughan ED, Tewari A. Grades of robotic nerve sparing J Urol. 2008 179 (4): 488 Suppl.
88. Chung DE, Lee R, **Te AE**. Transurethral Laser Enucleation of the Prostate (TLEP) - 2-Year Experience J Urol. 2009 181 (4):130 Suppl.
89. Tan GY, Jhaveri JK, Scott A, Dorsey PJ, Herman M, **Te AE**, Rao S, Tewari A. Biomechanical foundations for accelerated continence recovery after robotic-assisted radical prostatectomy J Urol. 2009 181 (4): 361 Suppl.
90. **Te AE**, Chung DE, Lee RI, Kaplan SA. Near-infrared Spectroscopy (NIRS) for Application in Urology J Urol. 2009 181 (4): 601 Suppl.
91. Lee R, **Te AE**, Kaplan SA, Sandhu JS. Temporal Trends in Adoption of and Indications for the Artificial Urinary Sphincter (AUS) J Urol. 2009 181 (4): 617 Suppl.
92. Kaplan SA, Chung DE, Sandhu JS, **Te AE**. Generic substitutes are neither as safe nor effective as branded medications: experience in men treated for lower urinary tract symptoms. J Urol. 2009 181 (4): 649 Suppl.
93. Kaplan SA, Chung DE, Sandhu JS, **Te AE**. Safety and efficacy concerns in switching patients with overactive bladder (OAB) symptoms from branded to generic anticholinergic medications. J Urol. 2009 181 (4): 675 Suppl.
94. Chung DE, **Te AE**, Staskin DR, Kaplan SA. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder (OAB) patients with prostates = 30 grams. J Urol. 2009 181 (4): 697 Suppl.
95. Chung DE, **Te AE**, Staskin DR, Kaplan SA. Efficacy and safety of tolterodine extended release and dutasteride in male OAB patients with prostates \geq 30 grams. Neurourology Urodynamics. 2009 28 (2):161.
96. Chung DE, Lee RK, Scofield S, Te T, **Te AE**. KTP laser photoselective vaporization of the prostate: 6-year experience. Neurourology Urodynamics 2009 28(2): 161.

Video Presentations and Publications:

1. **Te AE**, Kaplan SA: Transurethral electrovaporization of the prostate. *J Urol*.1995; 153: 48A.
2. **Te AE**, Kaplan SA: Transurethral electrovaporization of the prostate. *Video Urology Times*. 1995.
3. **Te AE**, Kaplan SA: Transurethral electrovaporization of the prostate., WHO-BPH Meeting. 1996
4. **Te AE**, Kaplan SA: Transurethral electrovaporization of the prostate., WHO-BPH Meeting. 1997
5. **Te AE**, Gonzalez: Photoselective Vaporization of the Prostate with the 80 Watt Quasicontinuous KTP Laser for the treatment of BPH., American College of Surgeons Annual Meeting. The 55th Cine-Clinic. 2004
6. Sandhu JS, **Te AE**. Photoselective vaporization of the prostate-The vaporization incision technique for large volume prostates. *J Urol* 2005, 173(4): 366.
7. Chung DE, Lee R, **Te AE**. Transurethral Laser Enucleation of the Prostate (TLEP) - 2-Year Experience *J Urol*. 2009 181 (4):130

Lectureships and Presentations: (selected 40 out of 130 events)

1. “Transurethral Electrovaporization of the Prostate”, Faculty Lecturer and Moderator, 1995 Annual Meeting of Society of Minimally Invasive Surgery, Portland, Oregon, 9/23/95.
2. “Transurethral Electrovaporization of the Prostate”, 1995 Annual International Meeting of the ESWL and Endourology Society, Jerusalem, Israel, 11/25/95.
3. “Medical Therapies for BPH”. Faculty Lecturer. 1996 Annual Philippine Chinese Medical Association, New York, NY 7/7/96.
4. “Electrovaporization of the Prostate”, Visiting Professor, Grand Rounds Lecture, University of Santo Tomas Medical School, Manila, Philippines, 9/25/96.
5. “Transurethral Electrovaporization of the Prostate”, Keynote Visiting Professor, 1996 Annual Japanese Urological Association Meeting, Tokyo, Japan, 12/12/96.
6. “New Therapies in BPH”. Faculty Lecturer. 1997 Annual Philippine Medical Association Meeting in US, New York, NY, 5/24/97.
7. “New Approaches to Management of the Overactive Bladder” Faculty Lecturer. 1998 Martin Stone OB/GYN Society Meeting. New York Academy of Medicine, New York, NY 10/23/98.
8. “Old versus New: Transvaginal Suspensions and Transvaginal Slings” The New York Academy of Medicine, NY, NY 7/10/99.
9. “Counterpoint: The holmium laser resection of the prostate”, NY Section AUA Annual Meeting, South Africa 10/24/00.
10. “Plenary Session Panel Presentation on Chronic Pelvic Pain Syndrome” AUA Annual Meeting 2003, Plenary Session Panel Member Chicago, Ill. 4/2003
11. “BPH Surgical Technology Session” AUA Annual Meeting 2003, Podium Session Moderator. Chicago, Ill. 4/2003
12. New York Section AUA Annual Meeting 2002, Madrid and Barcelona, Spain
 - 1.New Technologies in BPH 10/18/02
 - 2.Heat Therapies in Urology 10/22/02
 - 3.Is Chronic Prostatitis a Male Voiding Dysfunction 10/24/02

4. Photoselective Vaporization of the Prostate (PVP): Initial Experience with the 80 W High Power KTP Laser Vaporization Prostatectomy for the Treatment of BPH 10/24/02
13. AUA Educational National Postgraduate Course. Update on BPH: Faculty member, Keystone, Co. 1/8/03-1/12/03
14. New York Section AUA Annual Meeting 2003, Athens Greece
1. Evolution of the Laser Prostatectomy for BPH 10/14/03
 2. Combination Medical Therapy for BPH 10/14/03
 3. Cooled ThermoTherapy™ / TUMT® for Intractable Chronic Prostatitis – 12 Months after Treatment 10/14/03
 4. High power KTP Photoselective Laser Vaporization Prostatectomy for the Treatment of BPH in Men with Large Prostates J. S. Sandhu, B. A. VanderBrink, C. Egan, S. A. Kaplan, A. E. Te 10/14/03
15. New York Section AUA Annual Meeting 2004, Venice to Rome, Italy
Scientific Co- Chair and BPH Section Moderator
1. The 80 Watt Quasi Continuous KTP Laser Prostatectomy: The New York Presbyterian Experience: 10/04
 2. Where do new technologies for BPH fit? 10/04
 3. The USA Experience with the Next Generation High-Energy Microwave ThermoTherapy System (TUMT®) for Benign Prostatic Hyperplasia 10/04
16. Second Annual Maurice Gonder, M.D. Urology Symposium at SUNY Stony Brook, NY
- Minimally Invasive Technology in the Management of BPH: A 2005 Perspective 3/19/05
17. National Association for continence Annual Meeting 2005, Durham, NC 11/12/05
- The Male Bladder 11/12/05
- Prostate Health: Tackling BPH with medications and procedures 11/12/05
18. Annual New York Section AUA Meeting 2005, Vienna, Austria
- KTP Laser for Benign Prostatic Enlargement 9/19/05
19. SIU Meeting on Prostatic Diseases 2005, Bariloche, Pantagonia, San Carlos, Argentina
- Lunch Symposium: Innovations in Laser Treatment of BPH: Are All Lasers Created Equal? 9/30/05
20. AUA Annual Meeting 2005, San Antonio, Texas
- Plenary Session Presenter: BPH Highlights
 - Video Session Moderator, Laparoscopic and Robotic Nephroureterectomy, Cystectomy and Miscellaneous Procedures and Minimally Invasive BPH procedures.
 - Discussed Poster Session Moderator, Urologic Infections and Inflammatory Diseases
21. AUA Sponsored Course on BPH (Co-Director) Washington, DC. 12/9/05-12/12/05
Lectures given at course
- Debate Panel: The Role of Flow Rates, PVR's, TRUS, Prostate Biopsies and Urodynamics
 - Introduction to Treatment: What Are We Treating?
 - Role of Anticholinergic Therapy with LUTS
 - Overview of Invasive Surgical Therapies
22. AUA 2005 Post Graduate Course on BPH, Faculty member
- AUA Webcast Lecture

- Paradigms for Minimally Invasive Therapies for BPH 5/21/05
- 23. American Society of Laser Medicine and Surgery Annual Meeting 2006, Boston, Massachusetts
 - State of the Art Lecture- Photoselective Vaporization of the Prostate. 4/7/06
 - Point Counter Point Session- Greenlight vs. Holmium 4/7/06
- 24. American Urologic Association Meeting 2006 – CME Symposium
 - Emerging trends in prostatectomy and impact of new technologies; advanced techniques for large glands, difficult or challenging cases and managing patient expectations; tricks and tips. 5/19/06
- 25. Hong Kong Urologic Association: State of the Art Symposium on Photoselective Vaporization of the Prostate.Hong Kong.
 - Photoselective Vaporization of the Prostate: Surgical Tips and Caveats. 6/27/2006
- 26. Michigan Urologic Society Meeting 2006, Ann Arbor, Michigan
 - Resident Presentation Judge 5/10/06
 - State of the Art Lecture on Photoselective Vaporization of the Prostate 5/10/06
- 27. The 20th Congress of the Japanese Society of Endourology and ESWL 2006, Osaka, Japan
 - State of the Art Point Counterpoint: PVP vs HoLAP 10/6/06
- 28. Annual New York Section AUA Meeting, Buenos Aires, Argentina
 - Panelist on Panel Discussion: Male Voiding dysfunction: Best Medical Management on 11/13/07
 - Lecture: Anticholinergic for LUTS
- 29. R. Frank Jones Urological Society (RFJUS) of the National Medical Association (NMA) 2007 Annual Meeting and Scientific Assembly, Honolulu, Hawaii.
 - Faculty and Lecturer: Minimally Invasive Treatments for BPH: Which is best? 8/6/07
- 30. DOD Innovative Minds in Prostate Cancer Today (IMPACT) meeting, Atlanta, GA
 - Poster Presentation: Core per gram ratio predicts prostate cancer detection on transrectal ultrasound-guided prostate biopsy 09/07/08
- 31. Annual AUA Post Graduate Course on BPH, San Francisco, Ca
 - Course Director and Faculty 12/7-8/07
 - Lecture given at course:
 - Bladder Therapies for LUTS
 - Office Analgesia
 - Novel Minimally Invasive Investigational Therapies for BPH
 - Overview of Laser Therapies in BPH
 - The High Power 532 nm Laser Techniques
 - Laser Hands On
 - Thermotherapy Hands On Laboratory
 - Heated Battles: Which on to use?
- 32. 2008 Annual New York Section AUA Meeting, Berlin, Germany
 - Faculty Panelist on Panel Discussion: Male Voiding dysfunction: Best Medical Management on 11/13/08
 - Lecture: 532 nm Lasers in BPH:2008 update
- 33. 26th World Congress of Endourology and SWL Annual Meeting 2008, Shanghai, China. 12/2/08
 - BPH: Plenary Faculty Panel Member on Debate
 - Thulium vs. Holmium vs 532 nm Laser

34. 2008 ARTP (de l' Association pour la Recherche sur les Tumeurs de la Prostate) Annual Meeting, Paris, France on 12/5/08 Invited Plenary Faculty Member and Speaker
 - Molecular pathways of benign prostatic hyperplasia and my vision of BPH treatment in the next 10 years
35. AUA 2008 Post Graduate Course on Male Pelvic Health , Faculty member
Bladder Therapies in Men 05/17/2008 Orlando, FL
36. 26th World Congress of Endourology & SWL 2008
Faculty Member in Instructional Course 16 on Lasers in BPH on 12/02/08
532 nm Lasers In BPH: 2008 Update
37. AUA 2009 Post Graduate Course on Male Pelvic Health , Faculty member
Technology Update in Lower Urinary Tract Therapies in Men 05/24/2009 Chicago, Ill
38. AUA 2009 Post Graduate Course on Best Video Awards Course , Chairperson
and Faculty member 05/23/2009 Chicago, Ill
39. AUA 2009 Post Graduate Course on Laser Therapies for BPH: Hands On Course, Faculty
member 05/24/2009 Chicago, Ill
532 nm Lasers for BPH
40. 2009 Annual AUA Post Graduate Course on BPH, New Orleans, La.
Course Director and Faculty 3/6-7/2009
Lecture given at course:
 - Bladder Therapies for LUTS
 - Office Analgesia
 - Overview of Laser Therapies in BPH
 - The High Power 532 nm Laser Techniques
 - Laser Hands On Laboratory
 - Thermotherapy Hands On Laboratory

Date: _____

Signature: _____